27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
US biotech Vertex Pharmaceuticals has reported full-year product revenues of $7.57 billion for 2021, a 22% increase compared to 2020, while adjusted earnings were 26% higher at $13.02. 27 January 2022
T-cell immunotherapy developer Atara Biotherapeutics has entered into a long-term strategic agreement with Fujifilm Diosynth Biotechnologies (FDB), a subsidiary of FUJIFILM Corporation (Fujifilm) under which Fujifilm will acquire Atara’s T-Cell operations and manufacturing (ATOM) facility in Thousand Oaks, California for $100 million upfront, retaining current manufacturing and quality staff at the site. 27 January 2022
US biotech firm Orgenesis today announces it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Nino Jesus (Hospital) in Madrid, Spain. 27 January 2022
Calling MIG a leading German venture capital (VC) investment firm and one with a focus on life sciences and deep tech companies, might not do justice to the key role that it is playing in advancing some of Europe’s most promising biotech start-ups. 27 January 2022
A 30% drop in the share price of Alzheimer’s specialist Cortexyme has followed news of an abrupt change to its clinical research priorities. 27 January 2022
Replacing its retiring co-founder and chief executive Onno van de Stolpe, Belgium-based biotech Galapagos today announced that industry veteran Paul Stoffels will join the company as CEO effective April 1. 27 January 2022
Swiss pharma giant Roche recently announced that it will initiate a new Phase II trial to reassess its pipeline antisense therapy, tominersen, in the treatment of Huntington's disease (HD). 27 January 2022
America traded shares of Immunocore Holdings were up 3.2% at $22.62 mid-morning, having hit $24.06 in earlier activity, after the UK biotech announced approval from the US Food and Drug Administration of Kimmtrak (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). 26 January 2022
In another example of the growing popularity of the SPAC merger, digital medicine company Akili Interactive is to list on the Nasdaq in this way, with the deal expected to close in mid-2022. 26 January 2022
Russia plans to begin the production of a scarce drug based on ethosuximide for the treatment of epilepsy, according to recent statements by some of local analysts in the field of pharmaceutics and Russian media, reports The Pharma Letter’s local correspondent. 26 January 2022
US autoimmune drug developer Kyverna Therapeutics today announced it has closed an oversubscribed $85 million Series B financing round led by Northpond Ventures. 26 January 2022
Potentially curative gene therapies are among a number of exciting new sickle cell disease (SCD) drugs set to hit the US market, according to data and analytics company GlobalData. 26 January 2022
US biopharma firm Sierra Oncology yesterday announced positive top-line data from the pivotal Phase III MOMENTUM study - a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. 26 January 2022
Swiss contract development and manufacturing organization (CDMO) Lonza has reported full-year 2021 sales of 5.4 billion francs ($5.9 billion). 26 January 2022
Delaware’s Incyte, a developer of novel therapies to address serious unmet medical need, has stopped working on the small molecule parsaclisib and the novel antibody MCLA-145. 26 January 2022
Swedish immuno-oncology firm BioInvent, the first company to discover two innovative new cancer antibody targets, is fully funded to develop antibodies across five clinical projects over the coming three to four years. 26 January 2022
Checkpoint Therapeutics has announced positive topline results from its registration-enabling clinical trial of the novel checkpoint blocker cosibelimab. 25 January 2022